Capacity to serve global late-stage development and commercial manufacturing of monoclonal antibody drug substance to support new product launches
Brussels, Belgium – UCB, a global biopharmaceutical company, today announced it will build an innovative and environmentally sustainable multi-product biological manufacturing facility on their site in Braine l’Alleud, Wallonia, Belgium. The new biotechnology plant is being constructed to accompany the company’s growth and prepare for the launch and long-term supply of future medicines currently in clinical development.
The new facility, representing an investment of more than 300 million euros over the coming years, is expected to be operational in 2024. Construction is due to start in the first quarter of 2020. The biotechnology plant will be one of the largest and most modern in Belgium.
“The shift of our pipeline towards large molecules requires us to ramp up investment in mammalian technical development, as well as our manufacturing capabilities. We are convinced Braine l’Alleud is an ideal location for the implementation of this large-scale manufacturing facility. And the presence of our Biotech Sciences Team, Bio-Pilot plant and diverse research capabilities on the same site will ensure accelerated product launches and supply reliability,” said Dr. Kirsten Lund-Jurgensen, EVP and Head of Supply & Technology at UCB.
Construction of the new biomanufacturing plant will also have a positive effect on employment. UCB is expecting to create more than 150 new, high skilled jobs once the plant becomes fully operational.
For further information –
Corporate Communications
Laurent Schots
Media Relations, UCB
T+32.2.559.92.64 Laurent.schots@ucb.com
Investor Relations
Antje Witte
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com
Isabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com
Forward looking statements UCB
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.
Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. UCB is providing this information as of the date of this document and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
